Celyad S.A. | |
Stock Exchange | Euronext Brussels |
EPS |
EUR3.38 |
Market Cap |
EUR135.19 M |
Shares Outstanding |
11.94 M |
Public Float |
9.24 M |
Celyad S.A. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
11.52 M |
Public Float |
- |
Celyad S.A. ADR | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$3.99 |
Market Cap |
$154.53 M |
Shares Outstanding |
11.94 M |
Public Float |
- |
Address |
Axis Business Park Mont-Saint-Guibert WA 1435 Belgium |
Employees | - |
Website | http://www.celyad.com |
Updated | 07/08/2019 |
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium. |